Zacks Research Issues Negative Outlook for Chemours Earnings

The Chemours Company (NYSE:CC - Free Report) - Zacks Research reduced their Q3 2026 EPS estimates for shares of Chemours in a note issued to investors on Monday, May 19th. Zacks Research analyst R. Department now expects that the specialty chemicals company will earn $0.74 per share for the quarter, down from their prior estimate of $0.78. The consensus estimate for Chemours' current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours' Q4 2026 earnings at $0.45 EPS.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.06). The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.36 billion. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The firm's revenue for the quarter was up .4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.32 earnings per share.

A number of other brokerages have also recently issued reports on CC. Barclays dropped their target price on shares of Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 1st. BMO Capital Markets lowered their price target on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a report on Wednesday, February 19th. Truist Financial lowered their price target on shares of Chemours from $27.00 to $22.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Morgan Stanley lowered their price target on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a report on Monday, May 12th. Finally, Mizuho set a $15.00 price target on shares of Chemours in a report on Tuesday, April 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $17.56.

Chemours Stock Performance

Shares of CC stock traded up $0.32 on Thursday, reaching $10.62. The stock had a trading volume of 1,422,210 shares, compared to its average volume of 2,089,706. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The firm's 50-day moving average is $11.88 and its two-hundred day moving average is $15.89. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of 18.58 and a beta of 1.76. Chemours has a 12 month low of $9.33 and a 12 month high of $26.98.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Chemours by 8.3% in the first quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company's stock valued at $223,069,000 after acquiring an additional 1,263,047 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Chemours by 23.8% in the fourth quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company's stock valued at $73,907,000 after acquiring an additional 839,849 shares during the last quarter. Millennium Management LLC increased its stake in Chemours by 60.4% in the first quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company's stock valued at $54,428,000 after acquiring an additional 1,515,520 shares during the last quarter. American Century Companies Inc. boosted its position in Chemours by 17.5% in the first quarter. American Century Companies Inc. now owns 1,909,149 shares of the specialty chemicals company's stock valued at $25,831,000 after buying an additional 284,130 shares in the last quarter. Finally, Norges Bank acquired a new stake in Chemours in the fourth quarter valued at approximately $30,702,000. 76.26% of the stock is owned by institutional investors.

Insider Transactions at Chemours

In other news, CFO Shane Hostetter acquired 4,450 shares of the firm's stock in a transaction that occurred on Monday, May 19th. The shares were acquired at an average cost of $11.28 per share, with a total value of $50,196.00. Following the completion of the purchase, the chief financial officer now directly owns 59,694 shares of the company's stock, valued at $673,348.32. The trade was a 8.06% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.47% of the company's stock.

Chemours Dividend Announcement

The firm also recently announced a dividend, which will be paid on Monday, June 16th. Stockholders of record on Monday, May 19th will be issued a dividend of $0.0875 per share. The ex-dividend date is Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's dividend payout ratio is presently 175.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.